This PL Voices episode is a clip from one of our many editorial discussions.

This one took place on February 17, 2016 and is led by our Editor, Sherri Boehringer, PharmD, BCPS. You’ll hear the voices of Editorial Board members Steven E. Nissen, MD, MACC, Cleveland Clinic, Ohio; and Craig D. Williams, PharmD, FNLA, BCPS, Oregon Health and Science University. You’ll also listen to cardiovascular disease expert Suzanne Oparil, MD, FACC, FAHA, FASH, FAPS, University of Alabama at Birmingham. You can read our brief, to-the-point Recommendation and dive into the evidence-based details if you wish.

To learn more, visit pharmacistsletter.com.

PL Voices: ACE Inhibitors Versus ARBs

In order to listen you’ll need to subscribe to the brand NEW “Medication Talk” feed, just search for it in your favorite podcast app to make sure you don’t miss out.

https://trchealthcare.com/

Health & Fitness

Special guest Steven E. Nissen, MD, MACC, the Chief Academic Officer at the Heart and Vascular Institute, Lewis and Patricia Dickey Chair in Cardiovascular Medicine, and Professor of Medicine at the Cleveland Clinic Lerner School of Medicine at Case Western Reserve University joins us to talk about non-statins for LDL lowering. Listen in as they debate which non-statin to use for LDL lowering...due to recent headlines about bempedoic acid. You’ll also hear practical advice from panelists on TRC’s Editorial Advisory Board:Reid B. Blackwelder, MD, FAAFP, Associate Dean of Graduate and Continuing Medical Education at East Tennessee State UniversityAndrea Darby Stewart, MD, Associate Director, Family Medicine Residency at Honor HealthAnthony A. Donato, Jr., MD, MHPE, Associate Program Director, Internal Medicine from the Reading Health System, and Professor of Medicine at the Sidney Kimmel Medical College at Thomas Jefferson UniversityDouglas S. Paauw, MD, MACP, Professor of Medicine at the University of Washington School of MedicineCraig D. Williams, PharmD, FNLA, BCPS, Clinical Professor, Department of Pharmacy Practice at the Oregon Health and Science UniversityFor the purposes of disclosure, Dr. Steven Nissen reports relevant financial relationships [cardiology] with AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Esperion, Medtronic, MyoKardia, New Amsterdam Pharma, Novartis, Pfizer, Silence Therapeutics (grants/research support). The other speakers have nothing to disclose. All relevant financial relationships have been mitigated. Pharmacist’s Letter offers CE credit for this podcast. Log in to your Pharmacist’s Letter account and look for the title of this podcast in the list of available CE courses. If you’re not yet a Pharmacist’s Letter subscriber, find out more about our product offerings at trchealthcare.com.  Follow or subscribe, rate, and review this show in your favorite podcast app. You can also reach out to provide feedback or make suggestions by emailing us at ContactUs@trchealthcare.com. 

Non-Statins for LDL Lowering

Special guest Nicole Gastala, MD, Assistant Professor from the University of Illinois Chicago Department of Family Medicine and Director of Behavioral Health and Addiction at the Mile Square Health Center joins us to talk about opioid use disorder.

Listen in as they discuss big changes with buprenorphine prescribing for opioid use disorder.

You’ll also hear practical advice from panelists on TRC’s Editorial Advisory Board:Andrea Darby Stewart, MD, Associate Director, Family Medicine Residency at Honor HealthAnthony A. Donato, Jr., MD, MHPE, Associate Program Director, Internal Medicine from the Reading Health System, and Professor of Medicine at the Sidney Kimmel Medical College at Thomas Jefferson UniversityCraig D. Williams, PharmD, FNLA, BCPS, Clinical Professor, Department of Pharmacy Practice at the Oregon Health and Science UniversityNone of the speakers have anything to disclose. 

Pharmacist’s Letter offers CE credit for this podcast. Log in to your Pharmacist’s Letter account and look for the title of this podcast in the list of available CE courses.

If you’re not yet a Pharmacist’s Letter subscriber, find out more about our product offerings at trchealthcare.com. 

Follow or subscribe, rate, and review this show in your favorite podcast app. You can also reach out to provide feedback or make suggestions by emailing us at ContactUs@trchealthcare.com. 

Buprenorphine for Opioid Use Disorder

Special guest Steven E. Nissen, MD, MACC, the Chief Academic Officer at the Heart and Vascular Institute, Lewis and Patricia Dickey Chair in Cardiovascular Medicine, and Professor of Medicine at the Cleveland Clinic Lerner School of Medicine at Case Western Reserve University joins us to talk about medications for type 2 diabetes. Listen in as they debate whether metformin should still be first-line for all patients with type 2 diabetes...and discuss the role of GLP-1 agonists and SGLT2 inhibitors in these patients. You’ll also hear practical advice from panelists on TRC’s Editorial Advisory Board:Reid B. Blackwelder, MD, FAAFP, Associate Dean of Graduate and Continuing Medical Education at East Tennessee State UniversityAnthony A. Donato, Jr., MD, MHPE, Associate Program Director, Internal Medicine from the Reading Health System, and Professor of Medicine at the Sidney Kimmel Medical College at Thomas Jefferson UniversityCraig D. Williams, PharmD, FNLA, BCPS, Clinical Professor, Department of Pharmacy Practice at the Oregon Health and Science UniversityFor the purposes of disclosure, Dr. Steven Nissen reports a relevant financial relationship with AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Esperion, Medtronic, Novartis, Pfizer, Silence Therapeutics (grants/research support). The other speakers have nothing to disclose. All relevant financial relationships have been mitigated. Pharmacist’s Letter offers CE credit for this podcast. Log in to your Pharmacist’s Letter account and look for the title of this podcast in the list of available CE courses. If you’re not yet a Pharmacist’s Letter subscriber, find out more about our product offerings at trchealthcare.com.  Follow or subscribe, rate, and review this show in your favorite podcast app. You can also reach out to provide feedback or make suggestions by emailing us at ContactUs@trchealthcare.com. 

First-Line Meds for Type 2 Diabetes

Special guest Laila Khalid, MD, MPH from the Albert Einstein College of Medicine Montefiore Medical Center joins us to talk about new guidelines to reinforce safe opioid use. Listen in as they discuss what’s changed with the updated CDC opioid guidelines...and what to expect in your practice. You’ll also hear practical advice from panelists on TRC’s Editorial Advisory Board:Andrea Darby Stewart, MD, Associate Director, Family Medicine Residency at Honor HealthAnthony A. Donato, Jr., MD, MHPE, Associate Program Director, Internal Medicine from the Reading Health System, and Professor of Medicine at the Sidney Kimmel Medical College at Thomas Jefferson UniversityJoseph Scherger, MD, MPH, Family Physician, Primary Care 365, Eisenhower HealthNone of the speakers have anything to disclose. 

Pharmacist’s Letter offers CE credit for this podcast. Log in to your Pharmacist’s Letter account and look for the title of this podcast in the list of available CE courses.

If you’re not yet a Pharmacist’s Letter subscriber, find out more about our product offerings at trchealthcare.com. 

Follow or subscribe, rate, and review this show in your favorite podcast app. You can also reach out to provide feedback or make suggestions by emailing us at ContactUs@trchealthcare.com. 

New Opioid Guidelines

Headache medicine specialist Rebecca C. Burch, MD, joins us to talk about triptan use in patients with cardiovascular risk factors.

Listen in as they clear up confusion about which patients should avoid triptans due to cardiovascular concerns.

You’ll also hear practical advice from panelists on TRC’s Editorial Advisory Board:Anthony A. Donato, Jr., MD, MHPE, Associate Program Director, Internal Medicine from the Reading Health System, and Professor of Medicine at the Sidney Kimmel Medical College at Thomas Jefferson UniversitySteven E. Nissen, MD, MACC, the Chief Academic Officer at the Heart and Vascular Institute and the Lewis and Patricia Dickey Chair in Cardiovascular Medicine Professor of Medicine at the Cleveland Clinic Lerner School of Medicine at Case Western Reserve UniversityJoseph Scherger, MD, MPH, Family Physician, Primary Care 365, Eisenhower HealthCraig D. Williams, PharmD, FNLA, BCPS, Clinical Professor, Department of Pharmacy Practice at the Oregon Health and Science UniversityFor the purposes of disclosure, Dr. Steven Nissen reports a relevant financial relationship with AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Esperion, Medtronic, Novartis, Pfizer, Silence Therapeutics (grants/research support). The other speakers have nothing to disclose. All relevant financial relationships have been mitigated. Pharmacist’s Letter offers CE credit for this podcast. Log in to your Pharmacist’s Letter account and look for the title of this podcast in the list of available CE courses.

If you’re not yet a Pharmacist’s Letter subscriber, find out more about our product offerings at trchealthcare.com. 

Follow or subscribe, rate, and review this show in your favorite podcast app. You can also reach out to provide feedback or make suggestions by emailing us at ContactUs@trchealthcare.com. 

PL Voices: ACE Inhibitors Versus ARBs

Download our free app to listen on your phone